Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.80 |
| ▸ | TAF1 | P21675 | 10/20 | 0.80 |
| ▸ | CECR2 | Q9BXF3 | 8/20 | 0.80 |
| ▸ | BRD9 | Q9H8M2 | 7/20 | 0.64 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652264 | 0.90 | BRD4 (0.64) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL17753953 | 0.89 | CECR2 (0.81) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL17753998 | 0.89 | TAF1 (1.00) | BRD4TAF1CECR2BRD9 | |
| SCHEMBL17753558 | 0.88 | CECR2 (0.63) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL17753004 | 0.86 | CECR2 (0.80) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL17753570 | 0.82 | CECR2 (0.70) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL17753959 | 0.81 | BRD4 (0.72) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL17749044 | 0.80 | BRD4 (0.69) | BRD4TAF1CECR2BRD9ATAD2 | |
| SCHEMBL19658793 | 0.78 | CECR2 (0.80) | BRD4TAF1CECR2BRD9 | |
| SCHEMBL17753954 | 0.78 | CECR2 (1.00) | BRD4TAF1CECR2BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | BRD4 1/4885TAF1 439/4885CECR2 184/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | BRD4 1/4885TAF1 439/4885CECR2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.